Columvi is a cancer medicine used to treat adults with a blood cancer called diffuse large B-cell lymphoma (DLBCL) whose cancer has returned (relapsed) or stopped responding (refractory) after at least two previous treatments. DLBCL is rare, and [Columvi was designated an ‘orphan medicine’](/en/medicines/human/orphan-designations/eu-3-21-2497) (a medicine used in rare diseases) on 15 October 2021. Columvi contains the active substance glofitamab.
Therapeutic Indication
### Therapeutic indication Columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), after two or more lines of systemic therapy.
Therapeutic Area (MeSH)
ATC Code
L01FX28
ATC Item
glofitamab
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| Glofitamab | N/A | 格菲妥单抗 |
EMA Name
Columvi
Medicine Name
Columvi
Aliases
N/ANo risk management plan link.
